Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for CMO in Retinitis Pigmentosa
NCT02661711Phase 2Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in cystoid macular edema (CME), sponsored by Moorfields Eye Hospital. Primary endpoint: Central Macular Thickness at 12 months. Started Mar 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on NCT02661711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661711.